Peptides which mimic candida carbohydrate epitopes and their use in a vaccine

• US 6,403,090 B1
• Filed: 06/17/1999
• Issued: 06/11/2002
• Est. Priority Date: 05/23/1994
• Status: Expired due to Fees

• Current Assignee: Montana Inc.
• Original Assignee: Research and Development Institute, Inc.
• Inventors: Cutler, Jim E., Han, Yongmoon
• Primary Examiner(s): DUFFY, PATRICIA ANN
• Application Number:
  US09/334,922
• Time in Patent Office: 1,090 Days
• Field of Search: 530/387.1, 530/388.1, 530/388.4, 530/389.1, 530/389.5, 424/130.1, 424/137.1, 424/141.1, 424/150.1, 424/164.1
• US Class Current: 424/152.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0002 Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/40 from Candida
• CPC Class Codes: C07K 16/14 against material from fungi, algea or lichens
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids
• CPC Class Codes: C07K 7/08 having 12 to 20 amino acids gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68

Abstract

A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to infection by C. albicans. The composition includes phosphomannan of C. albicans, peptide mimotopes of phosphomannan epitopes, or polynucleotides encoding the peptide mimotopes. Monoclonal antibodies for use in passive immunization against candida infections are also provided.

Claims

1. An isolated passively immunizing antibody which binds specifically to the solubilized adhesin fraction of the β

-mercaptoethanol extract of the cell surface of Candida albicans.

2. The antibody of claim 1, wherein the adhesin fraction is part of the phosphomannoprotein complex of Candida albicans.

3. The antibody of claim 1, wherein the adhesin fraction is solubilized by extraction with β

-mercaptoethanol.

4. The antibody of claim 1, wherein the antibody is an antibody that binds to the same epitope as monoclonal antibody B6.1, American Type Culture Collection Accession Number HB11925.

5. The antibody of claim 4, wherein the antibody is the monoclonal antibody B6.1, American Type Culture Collection Accession Number HB11925.

9. A therapeutic composition comprising a therapeutically effective amount of the antibody of any of claims 1 to 8 and a carrier.

10. The therapeutic composition of claim 9, wherein the carrier is a pharmaceutically acceptable buffer.

11. A method for passive immunization against candidiasis comprising the step of administering to a patient in need thereof the composition of claim 9.

12. The method for passive immunization against candidiasis of claim 11, wherein the carrier is a pharmaceutically acceptable buffer.

13. A method for the treatment of disseminated candidiasis and mucocutaneous candidiasis comprising the step of administering to a patient in need thereof an effective amount of the composition of claim 9.

14. The method for the treatment of disseminated candidiasis and mucocutaneous candidiasis of claim 13, wherein the carrier is a pharmaceutically acceptable buffer.

15. The antibody of claim 2, wherein the antibody binds to a carbohydrate epitope.

6. An isolated passively immunizing antibody which binds specifically to an epitope of the solubilized adhesin fraction of Candida albicans, wherein the antibody binds to the same epitope as monoclonal antibody B6.1, American Type Culture Collection Accession Number HB11925.

7. The antibody of claim 6, wherein the adhesin fraction is part of the phosphomannoprotein complex of Candida albicans.

8. The antibody of claim 6, wherein the adhesin fraction is solubilized by extraction with β

-mercaptoethanol.